Border-associated macrophages: From physiology to therapeutic targets in Alzheimer's disease

被引:0
|
作者
Zheng, Fangxue [1 ]
Dong, Taiwei [2 ]
Chen, Yi [1 ]
Wang, Lang [1 ,3 ]
Peng, Guoping [1 ]
机构
[1] Zhejiang Univ, Dept Neurol, Affiliated Hosp 1, Sch Med, 79 Qing Chun Rd, Hangzhou 310002, Zhejiang, Peoples R China
[2] Hangzhou Normal Univ, Sch Basic Med Sci, Hangzhou, Peoples R China
[3] Zhejiang Univ, Sch Med, Interdisciplinary Inst Neurosci & Technol, Hangzhou, Peoples R China
基金
中国国家自然科学基金;
关键词
Alzheimer's disease; Border-associated macrophages; Perivascular macrophages; Antigen presentation; Neurovascular dysfunction; Neuroinflammation; PERIVASCULAR MACROPHAGES; COGNITIVE IMPAIRMENT; NEUROVASCULAR DYSFUNCTION; MYELOID CELLS; MICROGLIA; IMMUNE; SYSTEM; CONTRIBUTE; CLEARANCE; DYNAMICS;
D O I
10.1016/j.expneurol.2024.115021
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Border-associated macrophages (BAMs) constitute a highly heterogeneous group of central nervous system- resident macrophages at the brain boundaries. Despite their significance, BAMs have mainly been overlooked compared to microglia, resulting in a limited understanding of their functions. However, recent advancements in single-cell immunophenotyping and transcriptomic analyses of BAMs have revealed a previously unrecognized complexity in these cells, in addition to their critical roles under non-pathological conditions and diseases like Alzheimer's disease (AD), Parkinson's disease, glioma, and ischemic stroke. In this review, we discuss the origins, self-renewal capabilities, and extensive heterogeneity of BAMs, and clarify their important physiological functions such as immune monitoring, waste removal and vascular permeability regulation. We also summarize experimental evidence linking BAMs to the progression of AD. Finally, we review therapeutic strategies targeting brain innate immune cells mainly focusing on strategies aimed at modulating BAMs to treat AD and evaluate their potential in clinical applications.
引用
收藏
页数:13
相关论文
共 50 条
  • [41] Rho GTPases as therapeutic targets in Alzheimer’s disease
    Byron J. Aguilar
    Yi Zhu
    Qun Lu
    Alzheimer's Research & Therapy, 9
  • [42] Molecular and Therapeutic Targets of Genistein in Alzheimer’s Disease
    Kasi Pandima Devi
    Balakrishnan Shanmuganathan
    Azadeh Manayi
    Seyed Fazel Nabavi
    Seyed Mohammad Nabavi
    Molecular Neurobiology, 2017, 54 : 7028 - 7041
  • [43] Current therapeutic targets for the treatment of Alzheimer's disease
    Grill, Joshua D.
    Cummings, Jeffrey L.
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2010, 10 (05) : 711 - 728
  • [44] Neuroinflammation in Alzheimer’s Disease: from Pathogenesis to a Therapeutic Target
    Sanjay W. Pimplikar
    Journal of Clinical Immunology, 2014, 34 : 64 - 69
  • [45] Microglia in the Neuroinflammatory Pathogenesis of Alzheimer's Disease and Related Therapeutic Targets
    Cai, Yongle
    Liu, Jingliu
    Wang, Bin
    Sun, Miao
    Yang, Hao
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [46] Rho GTPases as therapeutic targets in Alzheimer's disease
    Aguilar, Byron J.
    Zhu, Yi
    Lu, Qun
    ALZHEIMERS RESEARCH & THERAPY, 2017, 9
  • [47] Are mitophagy enhancers therapeutic targets for Alzheimer's disease?
    Pradeepkiran, Jangampalli Adi
    Hindle, Ashly
    Kshirsagar, Sudhir
    Reddy, P. Hemachandra
    BIOMEDICINE & PHARMACOTHERAPY, 2022, 149
  • [48] IL-1β and CXCR4 as Potential Therapeutic Targets for Alzheimer's Disease
    Zhang, Yuhan
    Su, Qiong
    Tan, Jun
    Deng, Weiping
    Wan, Xiaoju
    Li, Yunjun
    Shu, Kuanyong
    COMBINATORIAL CHEMISTRY & HIGH THROUGHPUT SCREENING, 2024,
  • [49] Secretases as therapeutic targets for the treatment of Alzheimer's disease
    Dominguez, DI
    De Strooper, B
    Annaert, W
    AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS, 2001, 8 (02): : 124 - 142
  • [50] Molecular mechanisms of Alzheimer's disease: From therapeutic targets to promising drugs
    Alan, Elif
    Kerry, Zeliha
    Sevin, Gulnur
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2023, 37 (03) : 397 - 427